CU20110212A7 - Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades - Google Patents
Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedadesInfo
- Publication number
- CU20110212A7 CU20110212A7 CU20110212A CU20110212A CU20110212A7 CU 20110212 A7 CU20110212 A7 CU 20110212A7 CU 20110212 A CU20110212 A CU 20110212A CU 20110212 A CU20110212 A CU 20110212A CU 20110212 A7 CU20110212 A7 CU 20110212A7
- Authority
- CU
- Cuba
- Prior art keywords
- cancer
- diseases
- treatment
- pyrimidine
- new derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La invención se refiere a compuestos de la Fórmula (I): ESPACIO PARA LA FÓRMULA donde L1, R1, R2, R3, R4 y X son como se los define en la descripción. La presente invención también se refiere a procesos para la preparación de dichos compuestos, composiciones farmacéuticas que los contienen y su uso en el tratamiento de enfermedades, por ejemplo, cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18023809P | 2009-05-21 | 2009-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20110212A7 true CU20110212A7 (es) | 2012-03-15 |
Family
ID=42315702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20110212A CU20110212A7 (es) | 2009-05-21 | 2011-11-21 | Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades |
Country Status (23)
Country | Link |
---|---|
US (2) | US20120122867A1 (es) |
EP (1) | EP2432768B1 (es) |
JP (1) | JP5913093B2 (es) |
KR (1) | KR20120030436A (es) |
CN (1) | CN102482233A (es) |
AR (1) | AR078045A1 (es) |
AU (1) | AU2010250923A1 (es) |
BR (1) | BRPI1010937A2 (es) |
CA (1) | CA2760766A1 (es) |
CL (1) | CL2011002942A1 (es) |
CO (1) | CO6470845A2 (es) |
CR (1) | CR20110610A (es) |
CU (1) | CU20110212A7 (es) |
DO (1) | DOP2011000361A (es) |
EA (1) | EA201101650A1 (es) |
EC (1) | ECSP11011470A (es) |
IL (1) | IL216283A0 (es) |
MX (1) | MX2011012337A (es) |
SG (1) | SG175796A1 (es) |
TW (1) | TW201100083A (es) |
UY (1) | UY32648A (es) |
WO (1) | WO2010133885A1 (es) |
ZA (1) | ZA201109384B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2012DN02984A (es) | 2009-10-22 | 2015-07-31 | Gilead Sciences Inc | |
WO2012067269A1 (en) * | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Aminoalkoxyphenyl compounds and their use in the treatment of disease |
WO2012066336A1 (en) * | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
WO2012067268A1 (en) * | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Cyclic amide compounds and their use in the treatment of disease |
WO2012066335A1 (en) * | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Phenol compounds als toll -like receptor 7 agonists |
EP2651937B8 (en) | 2010-12-16 | 2016-07-13 | Sumitomo Dainippon Pharma Co., Ltd. | Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy |
WO2012080730A1 (en) | 2010-12-17 | 2012-06-21 | Astrazeneca Ab | Purine derivatives |
AU2012205681B2 (en) | 2011-01-10 | 2016-07-28 | Cleveland Biolabs, Inc. | Use of toll-like receptor agonist for treating cancer |
KR102058946B1 (ko) | 2011-04-08 | 2019-12-24 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염 치료를 위한 피리미딘 유도체 |
IN2014MN00862A (es) | 2011-11-09 | 2015-04-17 | Janssen R & D Ireland | |
FR2985256B1 (fr) * | 2011-12-30 | 2016-03-04 | Pitty Marc Henry | Derives piperazinyles pour le traitement de cancers |
BR112014019699B1 (pt) * | 2012-02-08 | 2021-12-07 | Janssen Sciences Ireland Uc | Derivados de piperidino-pirimidina, seu uso no tratamento de infecções virais e composição farmacêutica que os compreende |
ES2644702T3 (es) * | 2012-05-18 | 2017-11-30 | Sumitomo Dainippon Pharma Co., Ltd. | Compuestos de ácido carboxílico |
UA113651C2 (xx) | 2012-07-13 | 2017-02-27 | Макроциклічні пурини для лікування вірусних інфекцій | |
JP6283033B2 (ja) | 2012-10-05 | 2018-02-21 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染症およびさらなる疾患の処置のためのアシルアミノピリミジン誘導体 |
DK2906563T3 (en) | 2012-10-10 | 2018-06-06 | Janssen Sciences Ireland Uc | PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES |
PL2925729T3 (pl) | 2012-11-16 | 2018-04-30 | Janssen Sciences Ireland Uc | Heterocykliczne podstawione pochodne 2-amino-chinazoliny do leczenia infekcji wirusowych |
BR112015020118B1 (pt) * | 2013-02-21 | 2022-02-22 | Janssen Sciences Ireland Uc | Derivados de 2-aminopirimidina para o tratamento de infecções virais, composição farmacêutica e uso |
HUE031908T2 (en) | 2013-03-29 | 2017-08-28 | Janssen Sciences Ireland Uc | Macrocyclic deaza-purinones for the treatment of viral infections |
US10377738B2 (en) | 2013-05-24 | 2019-08-13 | Janssen Sciences Ireland Unlimited Company | Pyridone derivatives for the treatment of viral infections and further diseases |
BR112015032546B1 (pt) | 2013-06-27 | 2022-05-17 | Janssen Sciences Ireland Uc | Derivados de pirrolo[3,2-d]pirimidina e composição farmacêutica que os compreende para o tratamento de infecções virais e outras doenças |
EA036162B1 (ru) | 2013-07-30 | 2020-10-08 | Янссен Сайенсиз Айрлэнд Юси | Производные тиено[3,2-d]пиримидинов для лечения вирусных инфекций |
BR112017001796A2 (pt) | 2014-07-30 | 2018-02-14 | Cleveland Biolabs, Inc. | composições de flagelina e seus usos |
MA40774A (fr) * | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
WO2016109002A2 (en) | 2014-10-16 | 2016-07-07 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
PL3868741T3 (pl) | 2015-10-07 | 2024-01-29 | Sumitomo Pharma Co., Ltd. | Kompozycja zawierająca związek pirymidynowy i antygen pochodzący od patogenu |
MA45539A (fr) | 2016-07-01 | 2019-05-08 | Janssen Sciences Ireland Unlimited Co | Dihydropyranopyrimidines pour le traitement d'infections virales |
US10968184B2 (en) | 2016-09-29 | 2021-04-06 | Janssen Sciences Ireland Unlimited Company | Pyrimidine prodrugs for the treatment of viral infections and further diseases |
TWI808066B (zh) | 2016-12-05 | 2023-07-11 | 美商亞博創新醫藥有限公司 | 含有酸基之嘧啶化合物 |
US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
JP7169968B2 (ja) | 2017-03-29 | 2022-11-11 | 住友ファーマ株式会社 | ワクチンアジュバント製剤 |
CN111757755A (zh) | 2017-12-21 | 2020-10-09 | 大日本住友制药株式会社 | 包含tlr7激动剂的组合药物 |
WO2019166432A1 (en) * | 2018-02-28 | 2019-09-06 | F. Hoffmann-La Roche Ag | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer |
TW201945003A (zh) | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
AR114910A1 (es) | 2018-06-04 | 2020-10-28 | Apros Therapeutics Inc | Compuestos de pirimidina que contienen grupos ácidos |
TW202011986A (zh) | 2018-07-23 | 2020-04-01 | 公益財團法人日本健康科學振興財團 | 包含流感疫苗之組合物 |
BR112021015577A2 (pt) | 2019-02-08 | 2021-10-05 | Research & Business Foundation Sungkyunkwan University | Complexo-colesterol agonista do receptor toll-like 7 ou 8 e uso do mesmo |
WO2021177679A1 (ko) | 2020-03-02 | 2021-09-10 | 성균관대학교산학협력단 | 병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법 |
US20230355750A1 (en) | 2020-08-04 | 2023-11-09 | Progeneer Inc. | Kinetically acting adjuvant ensemble |
JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体7または8作用薬と機能性薬物の結合体およびその用途 |
WO2022031021A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1375162A (es) | 1970-10-22 | 1974-11-27 | ||
GB1546937A (en) | 1976-07-29 | 1979-05-31 | Beecham Group Ltd | 2,4-diaminopyrimidine derivatives |
ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
IL78643A0 (en) | 1985-05-02 | 1986-08-31 | Wellcome Found | Purine derivatives,their preparation and pharmaceutical compositions containing them |
DE3603577A1 (de) | 1986-02-06 | 1987-08-13 | Joachim K Prof Dr Seydel | Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit |
JPH08165292A (ja) | 1993-10-07 | 1996-06-25 | Techno Res Kk | アデニン誘導体、その製造法及び用途 |
US5994361A (en) | 1994-06-22 | 1999-11-30 | Biochem Pharma | Substituted purinyl derivatives with immunomodulating activity |
MX9702488A (es) | 1994-10-05 | 1998-04-30 | Darwin Discovery Ltd | Compuestos de purina y guanina como inhibidores de pnp. |
US6028076A (en) | 1996-07-03 | 2000-02-22 | Japan Energy Corporation | Purine derivative |
EP1035123B1 (en) | 1997-11-28 | 2003-08-20 | Sumitomo Pharmaceuticals Company, Limited | Novel heterocyclic compounds |
TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
JP4189048B2 (ja) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
EP1054871A2 (en) * | 1998-04-01 | 2000-11-29 | Du Pont Pharmaceuticals Company | Pyrimidines and triazines as integrin antagonists |
CA2341707C (en) * | 1998-08-27 | 2010-02-16 | Sumitomo Pharmaceuticals Co., Ltd. | Pyrimidine derivatives |
CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
WO2001007027A2 (en) | 1999-07-22 | 2001-02-01 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives for the treatment of viral diseases |
US20020128264A1 (en) | 2000-07-07 | 2002-09-12 | Taylor Eve M. | Methods for treatment of conditions affected by activity of multidrug transporters |
KR100892614B1 (ko) | 2001-04-17 | 2009-04-09 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 신규 아데닌 유도체 |
ATE470351T1 (de) * | 2001-11-22 | 2010-06-15 | Japan Science & Tech Agency | Nichtmenschliches tiermodell, das nicht auf eine immunopotenzierende synthetische verbindung anspricht |
JPWO2004003198A1 (ja) | 2002-06-27 | 2005-10-27 | 株式会社ジェノックス創薬研究所 | アレルギー性疾患の検査方法、および治療のための薬剤 |
BR0314761A (pt) | 2002-09-27 | 2005-07-26 | Sumitomo Pharma | Composto de adenina e seu uso |
KR20060016817A (ko) | 2003-06-20 | 2006-02-22 | 콜리 파마슈티칼 게엠베하 | 소분자 톨-유사 수용체 (tlr) 길항제 |
US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
CN1845745B (zh) * | 2003-09-05 | 2011-11-02 | 安那迪斯药品股份有限公司 | Tlr7配体及其前药在制备用于治疗丙型肝炎病毒感染的药物中的用途 |
OA13310A (en) | 2003-09-05 | 2007-04-13 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C. |
WO2005092892A1 (ja) | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | 8−オキソアデニン化合物 |
WO2005092893A1 (ja) | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | 9置換−8−オキソアデニン化合物 |
KR100700676B1 (ko) | 2005-06-24 | 2007-03-28 | (주) 비엔씨바이오팜 | 6―(4―치환된―아닐리노)피리미딘 유도체, 그 제조방법및 이를 포함하는 항바이러스용 약학적 조성물 |
JP2009508838A (ja) | 2005-09-15 | 2009-03-05 | オーキッド リサーチ ラボラトリーズ リミティド | 新規のピリミジン・カルボキサミド |
EP1939202A4 (en) | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW COMPOUND OF ADENINE |
JP2009541480A (ja) | 2006-06-30 | 2009-11-26 | アストラゼネカ アクチボラグ | 癌の治療において有用なピリミジン誘導体 |
CL2007002231A1 (es) | 2006-08-02 | 2008-04-11 | Basf Ag | Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico. |
WO2008083465A1 (en) | 2007-01-08 | 2008-07-17 | University Health Network | Pyrimidine derivatives as anticancer agents |
TW200902018A (en) * | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
WO2008114819A1 (ja) | 2007-03-20 | 2008-09-25 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
ES2452965T3 (es) | 2007-09-05 | 2014-04-03 | Rigel Pharmaceuticals, Inc. | Sal de xinafoato de N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-ona)-6-il]-5-fluoro-N2-[3-(metilaminocarbonilmetilenoxi)fenil]-2,4-pirimidindiamina |
PE20091236A1 (es) * | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
-
2010
- 2010-05-20 CA CA2760766A patent/CA2760766A1/en not_active Abandoned
- 2010-05-20 JP JP2012511356A patent/JP5913093B2/ja active Active
- 2010-05-20 KR KR1020117030498A patent/KR20120030436A/ko not_active Application Discontinuation
- 2010-05-20 SG SG2011078433A patent/SG175796A1/en unknown
- 2010-05-20 UY UY0001032648A patent/UY32648A/es not_active Application Discontinuation
- 2010-05-20 US US13/321,407 patent/US20120122867A1/en not_active Abandoned
- 2010-05-20 EP EP10721195.5A patent/EP2432768B1/en active Active
- 2010-05-20 BR BRPI1010937A patent/BRPI1010937A2/pt not_active IP Right Cessation
- 2010-05-20 AU AU2010250923A patent/AU2010250923A1/en not_active Abandoned
- 2010-05-20 EA EA201101650A patent/EA201101650A1/ru unknown
- 2010-05-20 WO PCT/GB2010/050825 patent/WO2010133885A1/en active Application Filing
- 2010-05-20 MX MX2011012337A patent/MX2011012337A/es not_active Application Discontinuation
- 2010-05-20 CN CN2010800338249A patent/CN102482233A/zh active Pending
- 2010-05-21 AR ARP100101776A patent/AR078045A1/es unknown
- 2010-05-21 TW TW099116416A patent/TW201100083A/zh unknown
-
2011
- 2011-11-10 IL IL216283A patent/IL216283A0/en unknown
- 2011-11-21 CL CL2011002942A patent/CL2011002942A1/es unknown
- 2011-11-21 CU CU20110212A patent/CU20110212A7/es unknown
- 2011-11-21 EC EC2011011470A patent/ECSP11011470A/es unknown
- 2011-11-21 DO DO2011000361A patent/DOP2011000361A/es unknown
- 2011-11-21 CR CR20110610A patent/CR20110610A/es unknown
- 2011-11-30 CO CO11165091A patent/CO6470845A2/es not_active Application Discontinuation
- 2011-12-20 ZA ZA2011/09384A patent/ZA201109384B/en unknown
-
2014
- 2014-08-26 US US14/469,515 patent/US9533978B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
SG175796A1 (en) | 2011-12-29 |
AU2010250923A1 (en) | 2011-11-17 |
DOP2011000361A (es) | 2011-12-15 |
US20150080396A1 (en) | 2015-03-19 |
WO2010133885A1 (en) | 2010-11-25 |
EA201101650A1 (ru) | 2012-07-30 |
CL2011002942A1 (es) | 2012-04-13 |
EP2432768A1 (en) | 2012-03-28 |
IL216283A0 (en) | 2012-01-31 |
CR20110610A (es) | 2012-01-09 |
CN102482233A (zh) | 2012-05-30 |
BRPI1010937A2 (pt) | 2019-09-24 |
ZA201109384B (en) | 2012-09-26 |
MX2011012337A (es) | 2011-12-08 |
CA2760766A1 (en) | 2010-11-25 |
JP5913093B2 (ja) | 2016-04-27 |
US9533978B2 (en) | 2017-01-03 |
CO6470845A2 (es) | 2012-06-29 |
KR20120030436A (ko) | 2012-03-28 |
TW201100083A (en) | 2011-01-01 |
UY32648A (es) | 2010-12-31 |
ECSP11011470A (es) | 2011-12-30 |
AR078045A1 (es) | 2011-10-12 |
US20120122867A1 (en) | 2012-05-17 |
EP2432768B1 (en) | 2017-07-05 |
JP2012527443A (ja) | 2012-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20110212A7 (es) | Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades | |
UY32611A (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
UY31183A1 (es) | Derivados de pirazinona y procesos para su preparación | |
CR20120264A (es) | Compuestos | |
BR112012029647A2 (pt) | novos derivados de pirimidinas | |
UY29002A1 (es) | Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia | |
SV2011003855A (es) | Heteroarilos sustituidos | |
UY31481A1 (es) | Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones | |
UY29803A1 (es) | Derivados de adeninas, composiciones farmacéuticas conteniéndolos, procedimientos de preparación y aplicaciones | |
UY30789A1 (es) | Derivados de adenina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
ECSP14013215A (es) | Compuestos novedosos | |
UY31905A (es) | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
UY33078A (es) | Derivados de imidazoquinolina | |
UY33337A (es) | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS | |
UY29795A1 (es) | Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones | |
UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
UY32916A (es) | Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones | |
UY29767A1 (es) | Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones | |
UY32494A (es) | Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones | |
UY29003A1 (es) | Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia | |
CR20150171A (es) | Benzamidas | |
UY32673A (es) | Nuevas pirimidinas, composiciones farmaceuticas que las contienen, procedimientos de preparaciones y su aplicacion como medicamentos | |
UY32744A (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 | |
CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
CL2010001432A1 (es) | Compuestos derivados de 2-oxo-alquil-1-piperazin-2-ona, afines por los receptores p75ntr; procedimiento para preparar los compuestos; compuesto intermediario; medicamento y composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos utiles para tratar enfermedades neurodegenerativas. |